We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical (MMSI) Now a Strong Buy on Estimate Revisions
Read MoreHide Full Article
On Aug 23, Zacks Investment Research raised Merit Medical Systems Inc. (MMSI - Free Report) to a Zacks Rank #1 (Strong Buy) on estimate revisions.
Why the Upgrade?
The upgrade was primarily driven by estimate revisions over the last 30 days.
The Zacks Consensus Estimate for full-year 2016 is currently pegged at 98 cents per share, which moved up a penny over the same time frame, as two out of four analysts revised their estimates upward.
Meanwhile, the Zacks Consensus Estimate for full-year 2017 has been revised upward by 2.6% (3 cents) to the present $1.17 per share, as three out of four analysts raised their projections.
The estimate revisions were primarily driven by Merit Medical’s strong second-quarter 2016 results. The company’s adjusted earnings of 26 cents per share outpaced the Zacks Consensus Estimate by couple of cents (8.3%). Sales of $151.7 million also managed to beat the Zacks Consensus Estimate of $148 million.
Sales increased 9.9% on a year-over-year basis at constant currency; driven by 9.6% growth in cardiovascular sales and 4.8% increase in endoscopy segment sales.
Merit Medical noted strong order growth from China, Japan, Russia, in addition to the United States in the quarter. The company’s results were also positively driven by robust performance in Australia and Canada.
Merit Medical announced the launch of two new HeRO products, the product line which it acquired from CryoLife , earlier this year. Additionally, the acquisition of DFINE Inc. will expand the company’s vertebral spine business (kyphoplasty and vertebralplasty) as well the oncology business.
Other Stocks to Consider
Other favorably ranked stocks include Masimo (MASI - Free Report) and Halyard Health . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Merit Medical (MMSI) Now a Strong Buy on Estimate Revisions
On Aug 23, Zacks Investment Research raised Merit Medical Systems Inc. (MMSI - Free Report) to a Zacks Rank #1 (Strong Buy) on estimate revisions.
Why the Upgrade?
The upgrade was primarily driven by estimate revisions over the last 30 days.
The Zacks Consensus Estimate for full-year 2016 is currently pegged at 98 cents per share, which moved up a penny over the same time frame, as two out of four analysts revised their estimates upward.
Meanwhile, the Zacks Consensus Estimate for full-year 2017 has been revised upward by 2.6% (3 cents) to the present $1.17 per share, as three out of four analysts raised their projections.
MERIT MEDICAL Price and Consensus
MERIT MEDICAL Price and Consensus | MERIT MEDICAL Quote
Key Growth Factors
The estimate revisions were primarily driven by Merit Medical’s strong second-quarter 2016 results. The company’s adjusted earnings of 26 cents per share outpaced the Zacks Consensus Estimate by couple of cents (8.3%). Sales of $151.7 million also managed to beat the Zacks Consensus Estimate of $148 million.
Sales increased 9.9% on a year-over-year basis at constant currency; driven by 9.6% growth in cardiovascular sales and 4.8% increase in endoscopy segment sales.
Merit Medical noted strong order growth from China, Japan, Russia, in addition to the United States in the quarter. The company’s results were also positively driven by robust performance in Australia and Canada.
Merit Medical announced the launch of two new HeRO products, the product line which it acquired from CryoLife , earlier this year. Additionally, the acquisition of DFINE Inc. will expand the company’s vertebral spine business (kyphoplasty and vertebralplasty) as well the oncology business.
Other Stocks to Consider
Other favorably ranked stocks include Masimo (MASI - Free Report) and Halyard Health . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>